Literature DB >> 8169379

Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses.

P A van Zwieten1, M Pfaffendorf.   

Abstract

Importance of L-channels for calcium: Calcium L-channels, the specific target of calcium antagonists, appear to be the receptors for these therapeutic agents. Therefore, the accessibility of these channels/receptors to calcium antagonists is a major determinant of the response to these drugs in cardiovascular disorders, including essential hypertension. As with numerous other drugs, the concentration at the receptor level and its time-course largely determine not only the intensity but also the rate of onset and the duration of the drug's effect. Disadvantages of nifedipine: Within the series of dihydropyridine calcium antagonists, the first compound introduced was nifedipine, a relatively hydrophilic drug. Owing to its hydrophilic character the drug rapidly reaches the receptor, thus explaining the rapid onset of its vasodilator action. Accordingly, reflex tachycardia develops, which is not only triggered by the degree of vasodilation but also by the rapidity of its onset. In addition, nifedipine has a short duration of action, requiring the use of special galenic formulations to allow one dose a day. New dihydropyridine calcium antagonists: In view of the disadvantages of the hydrophilic calcium antagonists, attempts have been made to develop dihydropyridines with a slower onset and a longer duration of action. This may be achieved by drugs which are largely in the ionized state at a physiological pH (e.g. amlodipine) and therefore combine slowly with the receptor and bind firmly to various tissue compartments. Another logical approach is the use of highly lipophilic drugs such as lacidipine. Because of its physicochemical properties, the effect in equilibrium is reached very slowly, after up to 5 h in isolated tissues and after more than 2 h after intravenous administration. Lacidipine appears to slowly enter a lipid compartment surrounding the dihydropyridine binding site, which has to be saturated before an equilibrium effect is reached. In addition, the persistence of the drug in this lipid compartment contributes to its long-lasting vasodilator effect.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8169379

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  8 in total

Review 1.  The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal.

Authors:  T F Lüscher; F Cosentino
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

2.  Nifedipine blocks Ca2+ store refilling through a pathway not involving L-type Ca2+ channels in rabbit arteriolar smooth muscle.

Authors:  T M Curtis; C N Scholfield
Journal:  J Physiol       Date:  2001-05-01       Impact factor: 5.182

Review 3.  A comparative review of the adverse effects of calcium antagonists.

Authors:  H T Dougall; J McLay
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

4.  Cell Cycle-Dependent Localization of Voltage-Dependent Calcium Channels and the Mitotic Apparatus in a Neuroendocrine Cell Line(AtT-20).

Authors:  Karen J Loechner; Wendy C Salmon; Jie Fu; Shipra Patel; James T McLaughlin
Journal:  Int J Cell Biol       Date:  2010-01-06

Review 5.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

6.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

7.  Nimodipine, a calcium channel blocker, delays the spontaneous LH surge in women with regular menstrual cycles: a prospective pilot study.

Authors:  Dan Nayot; Shany Klachook; Robert F Casper
Journal:  Reprod Biol Endocrinol       Date:  2013-02-07       Impact factor: 5.211

8.  Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling.

Authors:  Neha Woods; Jose Trevino; Domenico Coppola; Srikumar Chellappan; Shengyu Yang; Jaya Padmanabhan
Journal:  Oncotarget       Date:  2015-11-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.